Science Unmasked: Hedgehog Pathway Inhibitors Make Heroic Cancer Treatments

https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/81/77/51/817751f4-c8e8-b6a7-51e7-c22adc1f1ecb/mza_3625768391382589548.jpg/600x600bb.jpg

Disease Vs

Dr Daniel Andrews, Monash University

11 episodes

2 days ago

Disease Vs is all about diving into the biggest battles in modern science — from cancer to antibiotic resistance — and uncover how breakthroughs in biomedical research are reshaping how we treat diseases and deal with global heath challenges!

Science

RSS

All content for Disease Vs is the property of Dr Daniel Andrews, Monash University and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Science

https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_episode/43722824/43722824-1748328269626-8ba10ffdcff3c.jpg

Science Unmasked: Hedgehog Pathway Inhibitors Make Heroic Cancer Treatments

Disease Vs

19 minutes 59 seconds

5 months ago

Science Unmasked: Hedgehog Pathway Inhibitors Make Heroic Cancer Treatments

Drug resistance is a big problem in cancer treatment. Just when you think cancer has been defeated it can come back with a vengeance.

Adrian, Diya & Victoria explore the question "could targeting the hedgehog pathways for drug resistant cancers?" Tune in to find out!

References:

[1] World Health Organization (2024). Global cancer burden growing amidst mounting need for services. Geneva: WHO. Available from: https://www.who.int/news/item/01-02-2024-global-cancer-burden-growing--amidst-mounting-need-for-services

[2] Australian Institute of Health and Welfare (2023). Cancer data in Australia. Canberra: AIHW. Available from: https://www.aihw.gov.au/reports/cancer/cancer-data-in-australia/contents/overview

[3] Cancer Research UK (date unknown). Types of cancer. London: Cancer Research UK. Available from: https://www.cancerresearchuk.org/about-cancer/what-is-cancer/how-cancer-starts/types-of-cancer

[4] MedlinePlus (2022). Types of cancer treatment. Bethesda (MD): U.S. National Library of Medicine. Available from: https://medlineplus.gov/ency/patientinstructions/000901.htm

[5] National Cancer Institute (date unknown). What is cancer?. Bethesda (MD): National Cancer Institute. Available from: https://www.cancer.gov/about-cancer/understanding/what-is-cancer

[6] Nguyen, N.M., Cho, J. (2022). Hedgehog Pathway Inhibitors as Targeted Cancer Therapy and Strategies to Overcome Drug Resistance. International Journal of Molecular Sciences, 23(3), 1733.

[7] Jing, J., Wu, Z., Wang, J., et al. (2023). Hedgehog Signaling in Tissue Homeostasis, Cancers, and Targeted Therapies. Signal Transduction and Targeted Therapy, 8(1).

[8] Nguyen, N.M., Cho, J. (2022). Hedgehog Pathway Inhibitors as Targeted Cancer Therapy and Strategies to Overcome Drug Resistance. International Journal of Molecular Sciences, 23(3), 1733.

[9] Zito, P.M., Nassereddin, A., Scharf, R. (2021). Vismodegib. PubMed. Treasure Island (FL): StatPearls Publishing. Available from: https://www.ncbi.nlm.nih.gov/books/NBK513360/

[10] Wang, J., Chan, D.K.W., Sen, A., Ma, W.W., Straubinger, R.M. (2019). Tumor Priming by SMO Inhibition Enhances Antibody Delivery and Efficacy in a Pancreatic Ductal Adenocarcinoma Model. Molecular Cancer Therapeutics, 18(11), 2074–2084.

[11] Barker, C.A., Dufault, S., Arron, S.T., et al. (2024). Phase II Single-Arm Trial of Induction and Concurrent Vismodegib With Curative-Intent Radiation Therapy for Locally Advanced, Unresectable Basal Cell Carcinoma. Journal of Clinical Oncology, 42(19), 2327–2335.

[12] Xu, C., Wang, B., Xu, T., et al. (2025). EZH2 inhibitor and Vismodegib Synergistically Inhibit the Growth and Metastasis of Medulloblastoma. Medical Oncology, 42(6).

[13] Sekulic, A., Migden, M.R., Oro, A.E. et al. (2012). Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma. The New England Journal of Medicine, 366 (23), 2171-2179.

[14] Chang, A.L.S., Oro, M.R. (2012). Initial Assessment of Tumour Regrowth After Vismodegib in Advanced Basal Cell Carcinoma. Archive of Dermatology, 148(11), 1324.

[15] Atwood, S.X., Sarin, K.Y., Whitson, R.J. et al. (2015). Smoothened Variants Explain the Majority of Drug Resistance in Basal Cell Carcinoma. Cancer Cell, 27(3), 342-353.

[16] Danial, C., Sarin, K.Y., Oro, A.E., Chang, A.L.S. (2016). An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib. Clinical Cancer Research, 22(6), 1325-1329.

[17] Morinello, E., Pignatello, M., Villabruna, L., Goelzer, P., Burgin, H. (2014). Embryofetal Development Study of Vismodegib, a Hedgehog Pathway Inhibitor, in Rats. Birth Defects in Research Part B: Developmental and Reproductive Toxicology, 101(2), 135-143.